Malika Mirtukhtaeva; Ashley Grossman; Nitin Leekha; Alisher Akbutaev; Urmanova Yulduz

doi:10.1530/endoabs.81.EP767

EP767

Prev Next

Section Contents Cite

Endocrine Abstracts (2022) 81 EP767 | DOI: 10.1530/endoabs.81.EP767

ECE2022 Eposter Presentations Pituitary and Neuroendocrinology (211 abstracts)

‘The efficiency of the treatment by Sandostatin-Lar in patients with non-functional pituitary macroadenomas’

Malika Mirtukhtaeva ¹ , Ashley Grossman ² , Nitin Leekha ³ , Alisher Akbutaev ⁴ & Urmanova Yulduz ⁵

Err

Author affiliations

¹Republican Specialized Scientific Practical Medical Center of Endocrinology of Public Health Ministry named by acad. Ya.Kh. Turakulov, Tashkent, Uzbekistan; ²University of Oxford Senior Research Fellow, Green Templeton College, United Kingdom; ³Jaypee Hospital, Sector 128, Noida, India, Oncology Department, Noida, India; ⁴Republican Specialized Scientific Practical Medical Center of Endocrinology of Public Health Ministry named by acad. Ya.Kh. Turakulov, Department of Neurosurgery, Tashkent, Uzbekistan; ⁵Tashkent Pediatric Medical Institute, Department of Endocrinology, Tashkent, Uzbekistan

The purpose of the study: Is to study the efficiency of the treatment by Sandostatin-Lar in patients with non-functional pituitary macroadenomas (NFPA)

Material and methods.: Under our observation there were 20 patients with NFPA, of whom women were 8, men - 12. The average age of patients was 29,2/36.4 years. All patients were subjected to transnasal adenomectomy of pituitary gland (TAG) in our clinic. The whole patients were performed by research complex, which included Chemilyuminiscent hormonal (STH, IGF-1, Prolactin, LH, FSH, TSG, ACTH, Cortizol, etc.), ophthalmological (Eye bottom, field of view) and X-ray studies (CT, MRI of the Turkish saddle).

Results: According to our data, In all 20 patients, the average sizes of the pituitary tumor before TAG were in range 3.1 x 3.4 x 3.0 cm. Patients were divided into 2 groups: patients of 1 st group received after TAG the treatment by Sandostatin-Lar during 3 months, patients of 2 nd group not received Sandostatin-Lar\. The Sandostatin-Lar was prescribed 20 mg every 4 weeks for 3 months. The preliminary results showed the stabilization of the tumor residue in 7 of 10 patients (70%) in the group of combined treatment compared to 10 patients from 2 nd group who did not received Sandostatin-Lar.

Conclusions: It is necessary further continuation of research, taking into account immunocytochemical studies and biomarkers.